Advertisement: Cambridge Network
Advertisement: Simpsons Creative
Advertisement: Innova Systems
Advertisement: Mogrify
Advertisement: TTP
RealVNC mid-banner general
Advertisement: Wild Knight Vodka
Barr Ellison Solicitors – commercial property
Advertisement: RSM
Advertisement EY mid banner
ARM Innovation Hub
Advertisement: EBCam mid banner
RealVNC mid banner careers
Mid banner advertisement: BDO
16 July, 2019 - 11:04 By Kate Sweeney

Abcam acquires cell line portfolio from Chinese business

Cambridge life science research enabler Abcam has bought a cell line product portfolio from a Beijing specialist for an undisclosed sum.

UK quoted Abcam says the deal will enable the company to establish the same world leadership in the cell line market as it enjoys in antibodies.

Abcam, based at Cambridge Biomedical Campus, has acquired the entire live cell line and lysates portfolio of EdiGene Inc which is headquartered in Beijing with major operations in Guangzhou as well as Cambridge Massachusetts.

EdiGene developed the industry’s largest off-the shelf diploid - a cell or nucleus containing two complete sets of chromosomes, one from each parent. It has a library of over 2,800 single clonal knockout cell lines targeting over 2,600 genes in commonly used human cancer cell lines.

Ready-made diploid KO cell-lines are an important tool for antibody validation. They also play a significant role in the study and understanding of biological pathways and disease models and can be used in screening and cellular assays.

EdiGene’s cell lines and lysates are used by top academic researchers, global biopharmaceutical companies and leading antibody players. Cheri Walker, SVP of Corporate Development at Abcam, said: “We are excited to be able to bring the same level of industry-leading quality and data to the cell lines market as we have to research antibodies.

“The cell line market is in the early stages of development as a research tool, where the provision of more choice, with the right gene targets in the right cell lines, will allow the market to rapidly expand.”

Dong Wei, CEO of EdiGene, added: “Following our strategic decision to focus on advancing our pipeline of biotherapeutic products and high throughput genome screening services, we are pleased to be transitioning our complete cell line portfolio to the team at Abcam.

“As recognised industry leaders in the provision of biologic reagents and tools, we are confident Abcam will be able to provide expert support to our global user-base.”

Newsletter Subscription

Stay informed of the latest news and features